Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma
Brain metastasis is common after complete resection of LUAD and often occurs within 2 years. Markers of aggressive tumor biology, including higher maximum standardized uptake value, lymphovascular invasion, and <i>TP53</i> mutations, and neoadjuvant therapy are associated with brain metastasis.
Authors
- Gaetano Rocco (ORCID: https://orcid.org/0000-0003-4150-8604)
- Daniela Molena (ORCID: https://orcid.org/0000-0003-1655-4473)
- Puneeth Iyengar (ORCID: https://orcid.org/0000-0003-3740-7915)
- Bernard J. Park
- Nicolas Toumbacaris
- Matthew Joseph Bott (ORCID: https://orcid.org/0000-0003-0523-4028)
- Prasad S. Adusumilli (ORCID: https://orcid.org/0000-0002-1699-2046)
- Stijn Vanstraelen (ORCID: https://orcid.org/0000-0001-8432-1685)
- Elizabeth G. Dunne (ORCID: https://orcid.org/0009-0003-4914-382X)
- James Guoxian Huang (ORCID: https://orcid.org/0000-0001-5495-3577)
- Kay See Tan (ORCID: https://orcid.org/0000-0001-9757-1325)
- Brooke Mastrogiacomo (ORCID: https://orcid.org/0000-0003-0707-9738)
- Smita Sihag (ORCID: https://orcid.org/0000-0002-5041-3941)
- James M. Isbell (ORCID: https://orcid.org/0000-0002-7305-876X)
- Jamie E. Chaft (ORCID: https://orcid.org/0000-0002-5838-9982)
- David R. Jones
- Cameron N. Fick (ORCID: https://orcid.org/0000-0001-9528-0436)
- Daniel Gomez
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Molecular Oncology (United States) (US)
Publication Details
- Journal
- JTCVS Open
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.xjon.2024.09.030
- Citations
- 2
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Memorial Sloan-Kettering Cancer Center
- Boston Scientific Corporation
- Intuitive Surgical
- Invitae
- National Institutes of Health
- Genentech
- National Cancer Institute